Sangamo Biosciences reported $-47688000 in Net Income for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Acceleron Pharma XLRN:US $ -70.46M 6.94M
Alnylam Pharmaceuticals ALNY:US $ -204.51M 14.96M
Amgen AMGN:US $ 1884M 1420M
Avrobio Inc AVRO:US $ -32613000 1.23M
Bayer BAYN:GR € 85M 2420M
Biocryst Pharmaceuticals BCRX:US $ -58.8M 15.6M
Biogen BIIB:US $ 329.2M 119.3M
Biomarin Pharmaceutical BMRN:US $ -36.49M 49.44M
Bluebird Bio BLUE:US $ -216.82M 24.89M
Gilead Sciences GILD:US $ 2592M 1070M
GlaxoSmithKline GSK:LN 1168M 227M
Intercept Pharmaceuticals ICPT:US $ -3.63M 7.46M
IONIS PHARMACEUT IONS:US $ -82M 1.12M
Johnson & Johnson JNJ:US $ 3667M 2611M
Karyopharm Therapeutics KPTI:US $ -51812000 1.77M
Merk MRK:US $ 4567M 3022M
Novartis NOVN:VX SF 2758M 138M
Omeros OMER:US $ -22703000 5.89M
Pfizer PFE:US $ 8146M 2582M
Sangamo Biosciences SGMO:US $ -47.69M 0.52M
Sarepta Therapeutics SRPT:US $ -48.14M 33.26M
Ultragenyx Pharmaceutical RARE:US $ -73M 49.43M
Vertex Pharmaceuticals VRTX:US $ 851.93M 785M